Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain
- PMID: 17628496
- DOI: 10.1002/jnr.21417
Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain
Abstract
Intracellular accumulation of filamentous tau proteins is a defining feature of neurodegenerative diseases termed tauopathies. The pathogenesis of tauopathies remains largely unknown. Molecular chaperones such as heat shock proteins (HSPs), however, have been implicated in tauopathies as well as in other neurodegenerative diseases characterized by the accumulation of insoluble protein aggregates. To search for in vivo evidence of chaperone-related tau protein metabolism, we analyzed human brains with varying degrees of neurofibrillary tangle (NFT) pathology, as defined by Braak NFT staging. Quantitative analysis of soluble protein levels revealed significant positive correlations between tau and Hsp90, Hsp40, Hsp27, alpha-crystallin, and CHIP. An inverse correlation was observed between the levels of HSPs in each specimen and the levels of granular tau oligomers, the latter of which were isolated from brain as intermediates of tau filaments. We speculate that HSPs function as regulators of soluble tau protein levels, and, once the capacity of this chaperone system is saturated, granular tau oligomers form virtually unabated. This is expressed pathologically as an early sign of NFT formation. The molecular basis of chaperone-mediated protection against neurodegeneration might lead to the development of therapeutics for tauopathies. (c) 2007 Wiley-Liss, Inc.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease.Neurosci Res. 2006 Mar;54(3):197-201. doi: 10.1016/j.neures.2005.11.009. Epub 2006 Jan 6. Neurosci Res. 2006. PMID: 16406150
-
Granular tau oligomers as intermediates of tau filaments.Biochemistry. 2007 Mar 27;46(12):3856-61. doi: 10.1021/bi061359o. Epub 2007 Mar 6. Biochemistry. 2007. PMID: 17338548
-
Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.Prog Neurobiol. 2011 Jan;93(1):99-110. doi: 10.1016/j.pneurobio.2010.10.006. Epub 2010 Nov 5. Prog Neurobiol. 2011. PMID: 21056617 Review.
-
Excitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains.FEBS Lett. 2009 Jul 7;583(13):2194-200. doi: 10.1016/j.febslet.2009.06.015. Epub 2009 Jun 13. FEBS Lett. 2009. PMID: 19527721
-
Turning down tau phosphorylation.Nat Chem Biol. 2008 Aug;4(8):448-9. doi: 10.1038/nchembio0808-448. Nat Chem Biol. 2008. PMID: 18641620 Review.
Cited by
-
Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.J Biol Chem. 2013 Feb 8;288(6):4056-65. doi: 10.1074/jbc.M112.393751. Epub 2012 Dec 21. J Biol Chem. 2013. PMID: 23264626 Free PMC article.
-
Tau in neurodegenerative disease.Ann Transl Med. 2018 May;6(10):175. doi: 10.21037/atm.2018.04.23. Ann Transl Med. 2018. PMID: 29951497 Free PMC article. Review.
-
Therapeutic and diagnostic challenges for frontotemporal dementia.Front Aging Neurosci. 2014 Aug 19;6:204. doi: 10.3389/fnagi.2014.00204. eCollection 2014. Front Aging Neurosci. 2014. PMID: 25191265 Free PMC article. Review.
-
Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response.Exp Neurol. 2010 Jul;224(1):197-206. doi: 10.1016/j.expneurol.2010.03.011. Epub 2010 Mar 24. Exp Neurol. 2010. PMID: 20346943 Free PMC article.
-
Iron dyshomeostasis and ferroptosis in Alzheimer's disease: Molecular mechanisms of cell death and novel therapeutic drugs and targets for AD.Front Pharmacol. 2022 Sep 16;13:983623. doi: 10.3389/fphar.2022.983623. eCollection 2022. Front Pharmacol. 2022. PMID: 36188557 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous